NSCLC und SCLC*
- 20 October 2021
- journal article
- Published by Springer Science and Business Media LLC in InFo Hämatologie + Onkologie
- Vol. 24 (10), 44-52
- https://doi.org/10.1007/s15004-021-8835-z
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCThe New England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerThe New England Journal of Medicine, 2018
- Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and ChildrenThe New England Journal of Medicine, 2018
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialThe Lancet Oncology, 2016
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung CancerJournal of Clinical Oncology, 2014
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009